In their Comment about the use of corticosteroids to treat 2019 novel coronavirus (2019-nCoV) lung injury, Clark Russell and colleagues1 summarise the available clinical evidence on corticosteroid to treat patients with severe human coronavirus infections (severe acute respiratory syndrome [SARS] coronavirus and Middle East respiratory syndrome coronavirus), and other severe respiratory virus infections. In accordance with current WHO guidance,2 Russell and colleagues1 recommend that corticosteroids should not be used in 2019-nCoV-induced lung injury or shock, except in the setting of a clinical trial.
Original Article: [Correspondence] On the use of corticosteroids for 2019-nCoV pneumonia